Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 5.37IPCO.TO -0.2DC.A.TO 0.28NESN-SIX 0MCK 27.62GOOG -1.47XLV 0.985TEVA 0.82
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.44
+0.47 (1.66%)
as of Aug 25, 2026, 6:15:49 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

May 28, 2020

It is still very cheap in his opinion. It is cheaper than the market multiple. It is growing revenue, earnings and dividends as well as buying back stock. About a 4% dividend yield. A great management team. They merged their consumer business with GSK-N. There should be a boost to the share price when this gets IPOed in two to three years. In the near term there is their generic drug business that is merging with MYL-Q. They will then be an innovation-focused and higher growth R&D kind of Pfizer. (Analysts’ price target is $41.80)

Photo of Robert LauzonRobert Lauzon
Owned
Unlock Rating
$38.18

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
premiumPremium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

Pfizer Inc(PFE)

May 11, 2020
This week, Pfizer began vaccine trials in America. It has developed the MRNA vaccine with the German biotech BioNTech who will supervise trials in that country. Before, BioNTech was developing mRNA-based treatments for cancer. As trials continue, Pfizer says it will scale up its manufacturing capacity to ensure it can roll out the final, approved product if and when it is ready. Pfizer pays a robust 4% dividend and trades at 13x earnings at a profit margin over 31%. Like JNJ, Pfizer has returned to its highs.
Photo of The Monthly Gems by Allan TongThe Monthly Gems by Allan Tong
No
Unlock Rating
$38.10

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 25, 2020
Legislation handcuffs big pharma by letting patents expire and turn to generics. This stops these companies from growing revenue. Big pharma has to keep hitting home runs to survive. When they can't, they cut costs or amalgamate them. He prefers biotechs.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$33.93

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 11, 2020
They spinning off their low-growth businesses, so the remaining core will be a much higher-growth company. Their will put out an R&D investor update in late March that will be a catalyst for shares to rise. Their but drugs will expire in 2026-7, but their drug pipeline is good enough--they have bench strength. (Analysts’ price target is $43.15)
Photo of Jamie Murray Jamie Murray
Owned
Unlock Rating
$37.98

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 06, 2020
Trades at 14-15x earnings. Great dividend, almost 4%. Always pressure to develop drugs in the pipeline. Will have difficulty going into an election. Should do well over the long run.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$38.26

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jan 30, 2020
The only way they are growing is through massive cost cutting and acquisition. These stocks will all give you dividend growth and decent cash flow. One of their star pain killers is off patent.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$37.07

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 29, 2020
It's performed by cutting costs, not by growth. The reason is that as they develop new drugs, they go off-patent and lose billions. It's a cost story, simply. You're spinning your wheels here.
Photo of Gordon ReidGordon ReidUnlock Rating
$37.58

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 17, 2020
He takes a contrarian view as the company reorganizes its business. They are making acquisitions including in the oncology and vaccine business. There are some big drugs coming out of the pipeline. They are becoming more focused on R&D and building out their pipeline. They have around 15 phase 3 drugs right now. Patent expiry is what you have to watch for with this name. (Analysts’ price target is $42.54)
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$40.51

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jan 17, 2020

He was concerned that GSK was getting more growth focused. They spun off their consumer products with Novartis, giving up their oncology department. Now they have a joint venture with Pfizer. Having it as a longterm asset is probably positive.

Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$40.51

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 10, 2020
(A Top Pick Feb 08/19, Down 4%) All the drug stocks look so cheap here. His model price is $50.43.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$39.49

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 05, 2019
(A Top Pick Feb 08/19, Down 7%) All the drugs have been moving spectacularly. There is a lot of value. His model price is 48.79 or a 28% upside. If we have a fall, these stocks will do very well.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$38.03

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 21, 2019
(A Top Pick Dec 06/18, Down 13%) Under pressure due to patent loss and divesting off-patent division. Dividend is 3.9% and looks secure. Political noise has hurt healthcare. This is an opportunity. Starting to launch potential blockbuster drugs.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$37.74

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 19, 2019
(A Top Pick Sep 09/19, Up 4%) He doesn't see upside in the drug space. He won't sell it, but won't add to it. This sector will be quiet as others rally. Hold.
Photo of Elliott FishmanElliott Fishman
Owned
Unlock Rating
$37.66

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 24, 2019
Dropped off with the spinoff. Very good dividend. Undervalued here because of political pressure. That's an opportunity. Healthcare companies tend to do well when the economic cycle matures. Be patient. Value stocks are emerging from their underperformance. Yield is 4%. (Analysts’ price target is $41.77)
Photo of Stan WongStan Wong
Owned
Unlock Rating
N/A

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Oct 22, 2019
He liked this before, but has suffered a setback. The MFV is 37% higher than the present price. The earnings forecasts are rolling over, which worries him--it's a warning of bad things to come. He wouldn't buy this unless it fell to $30. Pays a 4% yield. Wait.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$36.43

Stock price when the opinion was issued

$28.38

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 211 to 225 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.69$101.18
TFPM 0$
OGC.TO 0.03$43.25
SLB -0.545$53.455
ARG.TO 0.53$8.75

Today's Top Picks

SII.TO 5.37$192.56
IPCO.TO -0.2$35.02
DC.A.TO 0.28$5.43
NESN-SIX 0$
MCK 27.62$901.41

Popular Articles

Latest Sell Signals

RKLB -1.16$67.12
INTC 0.36$87.62
MSFT 3.13$490.44
WSP.TO -3.61$188.67
CLS.TO 12.54$419.9

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like